Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.
What happened
FDA sent electronic requests for records on September 9 and September 27, 2022, to the email address in the company’s drug registration file. The company acknowledged the request on October 3, 2022, but did not provide the records, and FDA said phone messages on November 16, 2022, and September 6, 2023, also went unanswered. FDA said it therefore has no indication of the quality assurance for drugs registered as manufactured at the facility.
What FDA found
The company refused to let FDA access or copy records the agency requested about its OTC drug manufacturing, which the Federal Food, Drug, and Cosmetic Act prohibits.
Section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
What FDA wants
FDA tells the company to respond within 48 hours to confirm or update its drug registration and listing status and to say whether it will provide the requested records. If it no longer makes drugs, FDA says it must delist all previously listed drugs and deregister the facility.
Who should pay attention
- brands that buy OTC drug products from this manufacturer
- companies using the same contract manufacturer
- quality teams responsible for FDA registration and records requests
This is a summary. Read the original letter on fda.gov.